Sanofi to buy Bioverativ for $11.6bn
Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Sanofi will pay $105 per share of Bioverativ in cash, with the figure representing an equity value of approximately $11.6 billion.
The Paris-based company said that the acquisition, which was announced yesterday, January 22, will be immediately beneficial to its earnings per share in 2018.
Bioverativ generated $847 million in sales and $41 million in royalties in 2016. Its products—Eloctate (antihemophilic factor VIII [recombinant], Fc fusion protein) and Alprolix (coagulation factor IX [recombinant], Fc fusion protein)—treat haemophilia A and B respectively.
Aside from its two marketed products, Bioverativ’s pipeline includes a programme in phase 3 testing for cold agglutinin disease (an autoimmune disease), and early stage research programmes and collaborations in haemophilia, and other rare blood disorders.
According to Sanofi, the acquisition supports one of the priorities in its 2020 roadmap—reshaping its portfolio—by adding to a differentiated offering of innovative therapies.
Sanofi outlined its research and development strategy in December 2017. The changes comprise moving from licensing to proprietary assets, from small molecules to biologics, and from mono-targeting to multi-targeting compounds.
Olivier Brandicourt, Sanofi’s CEO, said: “Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ’s success in driving new standards of care with its extended half-life factor replacement therapies.”
John Cox, CEO of Bioverativ, added: “Bioverativ was created to bring meaningful progress to people living with haemophilia and other rare blood disorders, and I am extremely proud of the accomplishments we’ve made toward that mission over the past year.”
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
